Cargando…

Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy

BACKGROUND: Recently studies have identified a critical role for interferon regulatory factor (IRF) in modulating tumour immune microenvironment (TME) infiltration and tumorigenesis. METHODS: Based on IRF1-9 expression profiles, we classified all ccRCC samples into three molecular subtypes (clusters...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Can, Chen, Lin-Yuan, Yang, Rui-Xia, Zhang, Jie-Xin, Shao, Peng-Fei, Xu, Hua-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892447/
https://www.ncbi.nlm.nih.gov/pubmed/36741716
http://dx.doi.org/10.3389/fonc.2022.1118472
_version_ 1784881325146112000
author Chen, Can
Chen, Lin-Yuan
Yang, Rui-Xia
Zhang, Jie-Xin
Shao, Peng-Fei
Xu, Hua-Guo
author_facet Chen, Can
Chen, Lin-Yuan
Yang, Rui-Xia
Zhang, Jie-Xin
Shao, Peng-Fei
Xu, Hua-Guo
author_sort Chen, Can
collection PubMed
description BACKGROUND: Recently studies have identified a critical role for interferon regulatory factor (IRF) in modulating tumour immune microenvironment (TME) infiltration and tumorigenesis. METHODS: Based on IRF1-9 expression profiles, we classified all ccRCC samples into three molecular subtypes (clusters A-C) and characterized the prognosis and immune infiltration of these clusters. IRFscore constructed by principal component analysis was performed to quantify IRF-related subtypes in individual patients. RESULTS: We proved that IRFscore predicted multiple patient characteristics, with high IRFscore group having poorer prognosis, suppressed TME, increased T-cell exhaustion, increased TMB and greater sensitivity to anti- PD-1/CTLA-4 therapies. Furthermore, analysis of metastatic ccRCC (mccRCC) molecular subtypes and drug sensitivity proved that low IRFscore was more sensitive to targeted therapies. Moreover, IRFscore grouping can be well matched to the immunological and molecular typing of ccRCC. qRT-PCR showed differential expression of IRFs in different cell lines. CONCLUSIONS: Evaluating IRF-related molecular subtypes in individual ccRCC patients not only facilitates our understanding of tumour immune infiltration, but also provides more effective clinical ideas for personalised treatment.
format Online
Article
Text
id pubmed-9892447
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98924472023-02-03 Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy Chen, Can Chen, Lin-Yuan Yang, Rui-Xia Zhang, Jie-Xin Shao, Peng-Fei Xu, Hua-Guo Front Oncol Oncology BACKGROUND: Recently studies have identified a critical role for interferon regulatory factor (IRF) in modulating tumour immune microenvironment (TME) infiltration and tumorigenesis. METHODS: Based on IRF1-9 expression profiles, we classified all ccRCC samples into three molecular subtypes (clusters A-C) and characterized the prognosis and immune infiltration of these clusters. IRFscore constructed by principal component analysis was performed to quantify IRF-related subtypes in individual patients. RESULTS: We proved that IRFscore predicted multiple patient characteristics, with high IRFscore group having poorer prognosis, suppressed TME, increased T-cell exhaustion, increased TMB and greater sensitivity to anti- PD-1/CTLA-4 therapies. Furthermore, analysis of metastatic ccRCC (mccRCC) molecular subtypes and drug sensitivity proved that low IRFscore was more sensitive to targeted therapies. Moreover, IRFscore grouping can be well matched to the immunological and molecular typing of ccRCC. qRT-PCR showed differential expression of IRFs in different cell lines. CONCLUSIONS: Evaluating IRF-related molecular subtypes in individual ccRCC patients not only facilitates our understanding of tumour immune infiltration, but also provides more effective clinical ideas for personalised treatment. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9892447/ /pubmed/36741716 http://dx.doi.org/10.3389/fonc.2022.1118472 Text en Copyright © 2023 Chen, Chen, Yang, Zhang, Shao and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Can
Chen, Lin-Yuan
Yang, Rui-Xia
Zhang, Jie-Xin
Shao, Peng-Fei
Xu, Hua-Guo
Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy
title Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy
title_full Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy
title_fullStr Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy
title_full_unstemmed Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy
title_short Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy
title_sort identification of irf-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892447/
https://www.ncbi.nlm.nih.gov/pubmed/36741716
http://dx.doi.org/10.3389/fonc.2022.1118472
work_keys_str_mv AT chencan identificationofirfassociatedmolecularsubtypesinclearcellrenalcellcarcinomatocharacterizeimmunologicalcharacteristicsandguidetherapy
AT chenlinyuan identificationofirfassociatedmolecularsubtypesinclearcellrenalcellcarcinomatocharacterizeimmunologicalcharacteristicsandguidetherapy
AT yangruixia identificationofirfassociatedmolecularsubtypesinclearcellrenalcellcarcinomatocharacterizeimmunologicalcharacteristicsandguidetherapy
AT zhangjiexin identificationofirfassociatedmolecularsubtypesinclearcellrenalcellcarcinomatocharacterizeimmunologicalcharacteristicsandguidetherapy
AT shaopengfei identificationofirfassociatedmolecularsubtypesinclearcellrenalcellcarcinomatocharacterizeimmunologicalcharacteristicsandguidetherapy
AT xuhuaguo identificationofirfassociatedmolecularsubtypesinclearcellrenalcellcarcinomatocharacterizeimmunologicalcharacteristicsandguidetherapy